Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

64.50USD
26 May 2017
Change (% chg)

$-0.06 (-0.09%)
Prev Close
$64.56
Open
$64.37
Day's High
$64.75
Day's Low
$64.31
Volume
4,021,883
Avg. Vol
9,222,108
52-wk High
$88.85
52-wk Low
$63.88

Select another date:

Fri, May 12 2017

BRIEF-Gilead says stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director

* Gilead-Stockholders did not approve proposal requesting board take steps to adopt policy that chairman of board be independent director-sec filing Source text (http://bit.ly/2r9rtBo) Further company coverage:

Gilead profit falls as hepatitis C sales drop, shares down

Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2.5 percent.

UPDATE 2-Gilead profit falls as hepatitis C sales drop, shares down

May 2 Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2.5 percent.

Gilead net profit falls 25 percent on lower hepatitis C sales

May 2 Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2 percent.

BRIEF-Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

* Results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient populations

BRIEF-FDA approves two of Gilead's hepatitis C drugs for pediatric patients

* U.S. FDA approves new indications for Harvoni and Sovaldi in pediatric patients 12 years and older with chronic hepatitis C infection

BRIEF-Galapagos doses first psoriatic arthritis patient with filgotinib

* Galapagos NV - Galapagos doses first psoriatic arthritis patient with filgotinib

BRIEF-Gilead Sciences CEO John Milligan's 2016 total compensation was $13.9 mln- SEC Filing

* Gilead Sciences Inc- CEO John F. Milligan's 2016 total compensation was $13.9 million- SEC Filing

Gilead hepatitis C drug patent faces European challenge

LONDON International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.

Gilead hepatitis C drug patent faces European challenge

LONDON International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.

Select another date:

More From Around the Web